Molecular Templates Inc (MTEM)

[DFRANK1970]

I emailed Threshold Pharmaceuticals Inc. (THLD) investor relations on Thursday of last week and here's the response.

Investor Relations <[e-mail]>
Dec 11 (3 days ago)

to me
Dear Mr. Franklin:

Thank you for your note. Threshold management held a conference call on Monday morning, which may be helpful in answering your questions. The webcast replay can be accessed at http://edge.media-server.com/m/p/gb4w32i6.

We will be making decisions about all ongoing and planned studies with evofosfamide over the coming weeks. As stated on the conference call, we believe it is likely that Merck KGaA will terminate the partnership, and we expect to hear something definitive soon.

Beyond evofosfamide, our next most advanced drug candidate is tarloxotinib, which we are evaluating in two phase 2 studies. We expect to have preliminary data from those studies around the middle of 2016. (Tarloxotinib is not part of the Merck partnership.)

We expect to complete 2015 with approximately $40 to $45 million in cash, which we would hope to extend to the end of 2016. In the meantime, we will be thoughtfully evaluating strategic options pertaining to the future of the company and we will provide our shareholders with an update in the near term.

Thank you for your support of THLD.

Sincerely,

Laura Hansen

Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals, Inc.
170 Harbor Way, Suite 300
South San Francisco, CA 94080
E-mail: [e-mail]
Direct: 650-474-8206